Abstract
Background: HIV treatment programs in Africa typically approach all enrolling patients uniformly. Growing numbers of patients are antiretroviral experienced. Defining patients on the basis of antiretroviral experience may inform enrollment practices, particularly if medical outcomes differ. Methods: Baseline and follow-up measures (CD4, weight change, and survival) were compared in a retrospective analysis between antiretroviral-naive (ARV-N) and antiretroviral experience (ARV-E) patients enrolled at the Coptic Hope Center for Infectious Diseases in Nairobi, Kenya and followed between January 2004 and August 2006. Results: 1,307 ARV-N and 962 ARV-E patients receiving highly active antiretroviral therapy (HAART) were followed for median of 9 months (interquartile range: 4-16 months). Compared to ARV-N, ARV-E had substantially higher CD4 count (median cells/mm3, 193 versus 95, P < 0.001) and weight (median kg, 62 versus 57, P < 0.001) at baseline, and lower rates of change in CD4 (-9.2 cells/mm3/month; 95% CI, -11.4 – -7.0) and weight (-0.24 kg/month; 95% CI, -0.35 – - 0.14) over 12 months. Mortality was significantly higher in ARV-N than ARV-E (P = 0.001). Conclusions: ARV-E patients form a growing group that differs significantly from ARV-N patients and requires a distinct approach from ARV-N clients. Systematic approaches to streamline care of ARV-E patients may allow focused attention on early ARV-N clients whose mortality risks are substantially higher.
Keywords: Africa, HAART, HIV-1, clinic flow, experience, mortality
Current HIV Research
Title: Impact of Prior HAART Use on Clinical Outcomes in a Large Kenyan HIV Treatment Program
Volume: 7 Issue: 4
Author(s): Michael H. Chung, Alison L. Drake, Barbra A. Richardson, Ashok Reddy, Joan Thiga, Samah R. Sakr, James N. Kiarie, Paul Yowakim and Grace C. John-Stewart
Affiliation:
Keywords: Africa, HAART, HIV-1, clinic flow, experience, mortality
Abstract: Background: HIV treatment programs in Africa typically approach all enrolling patients uniformly. Growing numbers of patients are antiretroviral experienced. Defining patients on the basis of antiretroviral experience may inform enrollment practices, particularly if medical outcomes differ. Methods: Baseline and follow-up measures (CD4, weight change, and survival) were compared in a retrospective analysis between antiretroviral-naive (ARV-N) and antiretroviral experience (ARV-E) patients enrolled at the Coptic Hope Center for Infectious Diseases in Nairobi, Kenya and followed between January 2004 and August 2006. Results: 1,307 ARV-N and 962 ARV-E patients receiving highly active antiretroviral therapy (HAART) were followed for median of 9 months (interquartile range: 4-16 months). Compared to ARV-N, ARV-E had substantially higher CD4 count (median cells/mm3, 193 versus 95, P < 0.001) and weight (median kg, 62 versus 57, P < 0.001) at baseline, and lower rates of change in CD4 (-9.2 cells/mm3/month; 95% CI, -11.4 – -7.0) and weight (-0.24 kg/month; 95% CI, -0.35 – - 0.14) over 12 months. Mortality was significantly higher in ARV-N than ARV-E (P = 0.001). Conclusions: ARV-E patients form a growing group that differs significantly from ARV-N patients and requires a distinct approach from ARV-N clients. Systematic approaches to streamline care of ARV-E patients may allow focused attention on early ARV-N clients whose mortality risks are substantially higher.
Export Options
About this article
Cite this article as:
Chung H. Michael, Drake L. Alison, Richardson A. Barbra, Reddy Ashok, Thiga Joan, Sakr R. Samah, Kiarie N. James, Yowakim Paul and John-Stewart C. Grace, Impact of Prior HAART Use on Clinical Outcomes in a Large Kenyan HIV Treatment Program, Current HIV Research 2009; 7 (4) . https://dx.doi.org/10.2174/157016209788680552
DOI https://dx.doi.org/10.2174/157016209788680552 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
Call for Papers in Thematic Issues
HIV vaccine development
The development of a safe and effective vaccine that impedes HIV-1 transmission and/or limits the severity of infection remains a public health priority. The HIV-1/AIDS pandemic continues to have a disproportionate impact on vulnerable and under-served communities in the USA and globally. In the USA, minority communities that have relatively ...read more
Lymphomas in people living with HIV (PLWH)
In the era of combined antiretroviral therapy (cART), the incidence of lymphoma among people living with HIV (PLWH) surpassed Kaposi's sarcoma in 2011, becoming the most common AIDS-defining malignancy. The annual incidence rate ranges approximately from 100 to 300 per 100,000 individuals with HIV infection as the population denominator, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Biotransformation of Silybin and its Congeners
Current Drug Metabolism Endometriosis and Perinatal Outcome - A Systematic Review of the Literature
Current Women`s Health Reviews Multidrug-Resistant Gram-Negative Bacterial Infections: Are you Ready for the Challenge?
Current Clinical Pharmacology Vascular Endothelial Growth Factor (VEGF) as a Target of Bevacizumab in Cancer: From the Biology to the Clinic
Current Medicinal Chemistry Multifunctional Dendritic Drug Delivery Systems: Design, Synthesis, Controlled and Triggered Release
Current Topics in Medicinal Chemistry Cervical Cancer During Pregnancy – An Approach to Diagnosis and Management
Current Women`s Health Reviews Estrogen and Female Lower Urinary Tract Dysfunction
Current Women`s Health Reviews Discovery of New Inhibitors of Urease Enzyme: A Study Using STD-NMR Spectroscopy
Letters in Drug Design & Discovery Fertility Drugs and Ovarian Cancer
Current Cancer Drug Targets Radiotracers in Oncology
Current Radiopharmaceuticals Mucoadhesive Vaginal Drug Delivery Systems
Recent Patents on Drug Delivery & Formulation Carcinoma of the Lower Uterine Segment (LUS): Clinicopathological Characteristics and Association with Lynch Syndrome
Current Genomics A Five-microRNA Signature as Risk Stratification System in Uterine Corpus Endometrial Carcinoma
Combinatorial Chemistry & High Throughput Screening The Ultrasonographic Diagnosis of Polycystic Ovary Syndrome
Current Medical Imaging PREFACE [Hot topic: Current Concepts in Female Infertility Management (Part I) (Guest Editors: Sajal Gupta and Ashok Agarwal)]
Current Women`s Health Reviews GnRH-Analogues for Ovarian Protection in Childhood Cancer Patients: How Adult Hypotheses are Relevant in Prepubertal Females
Current Drug Targets The Need for Improvement of the Treatment of Advanced and Metastatic Cervical Cancer, the Rationale for Combined Chemo-Immunotherapy
Anti-Cancer Agents in Medicinal Chemistry A Novel Method for the Analysis of Soluble Carbohydrates from Cistanche deserticola
Current Analytical Chemistry Management of Early Stage Cervical Cancer
Reviews on Recent Clinical Trials Circulating Nucleic Acids in Plasma and Serum: Roles in Diagnosis and Prognosis in Diabetes and Cancer
Infectious Disorders - Drug Targets